- Home
- VMD vs CRDF Comparison
VMD vs CRDF Comparison
Compare VMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- CRDF
- Stock Information
- Founded
- VMD 2006
- CRDF 1999
- Country
- VMD United States
- CRDF United States
- Employees
- VMD N/A
- CRDF N/A
- Industry
- VMD
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VMD
- CRDF Health Care
- Exchange
- VMD Nasdaq
- CRDF Nasdaq
- Market Cap
- VMD 273.9M
- CRDF 210.2M
- IPO Year
- VMD N/A
- CRDF N/A
- Fundamental
- Price
- VMD $7.15
- CRDF $3.66
- Analyst Decision
- VMD
- CRDF Strong Buy
- Analyst Count
- VMD 0
- CRDF 5
- Target Price
- VMD N/A
- CRDF $10.50
- AVG Volume (30 Days)
- VMD 214.8K
- CRDF 1.5M
- Earning Date
- VMD 08-06-2025
- CRDF 08-07-2025
- Dividend Yield
- VMD N/A
- CRDF N/A
- EPS Growth
- VMD 19.95
- CRDF N/A
- EPS
- VMD 0.30
- CRDF N/A
- Revenue
- VMD $232,793,000.00
- CRDF $587,000.00
- Revenue This Year
- VMD $17.35
- CRDF N/A
- Revenue Next Year
- VMD $12.87
- CRDF N/A
- P/E Ratio
- VMD $23.87
- CRDF N/A
- Revenue Growth
- VMD 19.97
- CRDF N/A
- 52 Week Low
- VMD $6.14
- CRDF $2.01
- 52 Week High
- VMD $9.81
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- VMD 63.23
- CRDF 58.81
- Support Level
- VMD $6.80
- CRDF $3.07
- Resistance Level
- VMD $7.08
- CRDF $3.24
- Average True Range (ATR)
- VMD 0.20
- CRDF 0.23
- MACD
- VMD 0.05
- CRDF 0.00
- Stochastic Oscillator
- VMD 93.85
- CRDF 67.96
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.